Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Holdings Lifted by Machina Capital S.A.S.

Machina Capital S.A.S. boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 96.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 3,924 shares of the medical research company’s stock after acquiring an additional 1,924 shares during the period. Thermo Fisher Scientific comprises about 1.3% of Machina Capital S.A.S.’s holdings, making the stock its 3rd biggest holding. Machina Capital S.A.S.’s holdings in Thermo Fisher Scientific were worth $2,083,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of TMO. Raleigh Capital Management Inc. lifted its stake in Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after purchasing an additional 27 shares in the last quarter. Cedar Mountain Advisors LLC grew its holdings in Thermo Fisher Scientific by 107.0% in the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock valued at $47,000 after buying an additional 46 shares in the last quarter. Operose Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 250.0% in the third quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 75 shares during the period. Financial Connections Group Inc. purchased a new position in Thermo Fisher Scientific during the fourth quarter worth about $53,000. Finally, Valley National Advisers Inc. grew its stake in shares of Thermo Fisher Scientific by 40.5% in the 3rd quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock valued at $56,000 after buying an additional 32 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.1 %

Shares of Thermo Fisher Scientific stock traded down $0.68 during trading hours on Tuesday, reaching $572.87. The stock had a trading volume of 1,767,748 shares, compared to its average volume of 1,539,120. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The firm has a market capitalization of $218.67 billion, a price-to-earnings ratio of 36.79, a P/E/G ratio of 2.37 and a beta of 0.80. The firm has a 50 day simple moving average of $575.59 and a two-hundred day simple moving average of $534.36.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The company had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.64 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is 10.01%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $74,039,491.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The disclosure for this sale can be found here. Insiders have sold 62,277 shares of company stock worth $35,373,364 in the last ninety days. 0.34% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. JPMorgan Chase & Co. raised their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. HSBC increased their target price on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a report on Thursday, April 25th. Raymond James upped their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Finally, Royal Bank of Canada lifted their target price on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $607.35.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.